Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid in a 46-year-old woman.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314697 | PMC |
| http://dx.doi.org/10.1136/bcr-2020-241086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sclerosing Mucoepidermoid Carcinoma With Eosinophilia of the Thyroid: A Rare Case From Georgia and a Comprehensive Literature Review.
Cureus
October 2024
Department of Pathology and Forensic Medicine, Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, GEO.
Sclerosing mucoepidermoid carcinoma with eosinophilia (SMECE) is a rare thyroid malignancy typically linked to chronic lymphocytic thyroiditis. We present the first documented case of SMECE in Georgia, involving a 41-year-old woman with Hashimoto's thyroiditis. A 16 mm hypoechoic thyroid nodule was detected on routine ultrasound, and fine needle aspiration categorized it as Bethesda V.
View Article and Find Full Text PDFSclerosing mucoepidermoid carcinoma of salivary glands.
Virchows Arch
November 2024
Department of Pathology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Sclerosing mucoepidermoid carcinoma (SMEC) of the salivary glands is a rare variant of low-grade mucoepidermoid carcinoma with scanty cellular atypia characterized by marked fibrosis/sclerosis and a rich inflammatory infiltrate. Herein, we report 25 unpublished cases of SMEC, two of them with prominent eosinophilia (2/25; 8%) and three with abundant IgG4-positive plasma cells (3/25; 12%). In our series of salivary SMEC, molecular analysis using fluorescence in situ hybridization (FISH) and/or next-generation sequencing (NGS) provided evidence of MAML2 gene rearrangement in 18 cases of the 21 analyzable cases tested (86%), while this gene locus was intact in 3 cases (14%).
View Article and Find Full Text PDFUnusual Presentation of a Parotid Gland Malignancy: A Case Report.
Cureus
August 2024
Oral and Maxillofacial Surgery, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND.
The most commonly occurring malignant salivary gland tumor is mucoepidermoid carcinoma (MEC). It consists of intermediate cells, squamous cells, and mucous-secreting cells. It is usually not capsulated and is identified by mucocarmine staining.
View Article and Find Full Text PDFMAML2-rearrranged sclerosing mucoepidermoid carcinoma of submandibular gland: an incidental finding in a patient with history of recurrent sialadenitis and Sjögren's syndrome.
Oral Surg Oral Med Oral Pathol Oral Radiol
November 2024
Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
The Sclerosing subtype of mucoepidermoid carcinoma is rare, with only 39 cases reported in literature. We present a new case of sclerosing mucoepidermoid carcinoma (SMEC) with MAML2 rearrangements. A 49-year-old woman with Sjögren's syndrome experienced recurrent submandibular sialadenitis and sialolithiasis, leading to the removal of her right gland.
View Article and Find Full Text PDFUpdate of newly-recognized salivary gland neoplasms: molecular and immunohistochemical findings and clinical importance.
Histopathology
January 2025
Department of Pathology, The University of Chicago, Chicago, IL, USA.
With the advancement of molecular testing and the routine use of immunohistochemical stains, salivary gland tumours previously categorized as adenoma or adenocarcinoma, not otherwise specified, are being reclassified with distinct diagnoses. Newly recognized benign entities include: sclerosing polycystic adenoma, keratocystoma, intercalated duct hyperplasia and adenoma, and striated duct adenoma. Newly recognized malignant salivary gland tumours include: microsecretory adenocarcinoma, sclerosing microcytic adenocarcinoma, and mucinous adenocarcinoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!